--- title: 'Director / Senior Director, Pharmacovigilance Operations at Rezolute' canonical: 'https://feeny.ai/job/director-senior-director-pharmacovigilance-operations-rezolute-remote-dnq13sn8dzh0' type: 'job' last_seen: '2026-10-16' --- # Director / Senior Director, Pharmacovigilance Operations at Rezolute - **Company:** Rezolute - **Location:** Remote - **Employment:** full-time - **Work type:** remote - **Posted:** 2026-10-02 - **Last confirmed live:** 2026-10-16 - **Apply:** https://jobs.lever.co/rezolutebio/675c142f-0d35-418e-a9c5-d10d8e376dd5 ## Job description Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation, collaboration, and integrity. Rezolute’s lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage clinical development for the treatment of hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI). As Rezolute expands its medical and scientific focus into tumor-related hyperinsulinism (tumor HI), most commonly related to pancreatic neuroendocrine tumors (insulinomas) or paraneoplastic hypoglycemia (NICTH), the company is committed to advancing novel therapeutic strategies that address this rare and complex form of hypoglycemia associated with insulin-secreting tumors and related neuro-oncology disorders More information can be found at rezolutebio.com The Director / Senior Director, PharmacovigilanceOperations will play a critical leadership role in building and executing the company’s pharmacovigilance and drug safety capabilities as the organization advances its lead product toward regulatory approval and commercial launch. This individual will be responsible for ensuring an effective, scalable, and inspection-ready pharmacovigilance system supporting late-stage clinical development, regulatory submissions, product launch, and post-marketing safety surveillance. The role will provide leadership across safety operations, benefit-risk management, signal detection and management, aggregate reporting, safety governance, vendor oversight, and global regulatory compliance. As the company evolves from a development-stage organization to a commercial biopharmaceutical company, the Director/Senior Director will help establish the people, processes, systems, governance, and external partnerships required for commercial pharmacovigilance. The successful candidate will combine strong scientific and medical judgment with practical operational experience implementing pharmacovigilance capabilities in a growing organization. ## Key Responsibilities Pharmacovigilance Strategy & Leadership - Develop and execute the pharmacovigilance strategy supporting late-stage clinical development, regulatory approval, product launch, and post-marketing surveillance. - Establish a scalable PV operating model appropriate for the company's anticipated commercial footprint, product portfolio, geographic expansion, and partnership structure. - Serve as a senior safety leader and subject matter expert for pharmacovigilance matters across Clinical Development, Regulatory Affairs, Medical Affairs, Quality, Commercial, Legal, and other functions. - Provide safety input into clinical development plans, regulatory submissions, labeling strategies, launch-readiness activities, medical information processes, and lifecycle management. - Represent Pharmacovigilance on cross-functional governance and product development teams. - For the Senior Director level, provide strategic leadership to executive management regarding emerging safety issues, benefit-risk considerations, regulatory risk, and organizational PV capabilities. Commercial Launch Readiness - Lead PV readiness activities required to transition from a clinical-stage to commercial-stage pharmacovigilance organization. - Develop and maintain a comprehensive PV launch-readiness plan, including commercial adverse event intake, case processing, reconciliation, vendor interfaces, escalation pathways, reporting responsibilities, and business continuity. - Establish processes for adverse event and product complaint intake from Medical Affairs, Medical Information, Commercial, Market Access, patient support programs, digital channels, distributors, partners, and other potential sources. - Partner with Quality and Commercial functions to ensure appropriate identification, triage, reconciliation, and escalation of safety information associated with product complaints. - Establish PV requirements and training for employees, contractors, vendors, field-based personnel, and other groups who may receive adverse event information. - Ensure PV systems, procedures, resources, vendors, and governance structures are operational and inspection-ready prior to product launch. Safety Surveillance & Benefit-Risk Management - Establish and oversee processes for signal detection, validation, prioritization, assessment, management, and documentation. - Lead cross-functional safety review or Safety Management Team meetings. - Provide strategic oversight of aggregate safety reports and periodic benefit-risk assessments, including applicable DSURs, PBRERs/PSURs, and other periodic reports. - Lead or contribute to Risk Management Plans and other risk minimization activities. - Partner with Regulatory Affairs and Clinical Development on safety-related labeling changes, investigator communications, regulatory responses, and health authority interactions. Pharmacovigilance Operations - Provide strategic and operational oversight of adverse event case management across clinical and post-marketing sources. - Ensure appropriate collection, assessment, processing, follow-up, quality review, and submission of ICSRs within applicable regulatory timelines. - Oversee PV vendors, including safety database providers, case-processing vendors, medical review resources, literature surveillance providers, and aggregate reporting partners. - Establish meaningful operational metrics, quality indicators, and vendor performance measures to monitor the effectiveness of the PV system. - Develop internal capabilities versus outsourced capabilities based on company growth, volume, geographic footprint, and portfolio requirements. - Ensure effective reconciliation of safety information across clinical databases, medical information, quality/product complaints, partners, patient support programs, and other relevant systems. PV Quality, Compliance & Inspection Readiness - Partner closely with Quality Assurance to establish and maintain the company's pharmacovigilance quality system. - Develop, implement, and maintain PV policies, SOPs, work instructions, and controlled processes. - Establish appropriate deviation, CAPA, quality-event, and compliance-monitoring processes related to pharmacovigilance. - Maintain continuous PV inspection readiness and participate in regulatory authority inspections, partner audits, vendor audits, and internal audits. - Ensure documentation demonstrates effective oversight of outsourced PV activities. - Support development and maintenance of applicable PV system documentation and regulatory requirements, including the Pharmacovigilance System Master File (PSMF) where required. Partnerships & Alliance Management - Develop and maintain Safety Data Exchange Agreements (SDEAs) and pharmacovigilance provisions within licensing, distribution, co-development, and commercialization agreements. - Establish clear responsibilities for case exchange, aggregate reporting, signal management, regulatory submissions, reconciliation, and safety governance. - Represent the company on joint safety committees and other alliance governance forums. - Monitor partner compliance with contractual PV obligations and implement corrective actions as necessary. Regulatory Compliance - Maintain current knowledge of applicable global pharmacovigilance regulations and guidance, including requirements of the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), ICH, and other relevant health authorities. - Ensure company PV processes remain compliant as products transition from investigational to marketed status and expand geographically. - Support preparation for health authority meetings and responses to regulatory questions regarding product safety and benefit-risk. ## Qualifications Education - Advanced degree in a health or life sciences discipline strongly preferred, such as MD, PharmD, PhD, RN/NP, or equivalent scientific/medical training. - Candidates with a master's or bachelor's degree and significant relevant pharmacovigilance leadership experience may also be considered. ## Experience Director: - Typically 10+ years of pharmaceutical/biotechnology industry experience, including approximately 7+ years in pharmacovigilance/drug safety. - Demonstrated experience supporting late-stage clinical development and/or marketed products. - Experience managing outsourced PV operations and vendors. - Previous experience with NDA/BLA/MAA preparation, product launch, or post-marketing pharmacovigilance strongly preferred. Senior Director: - Typically 12-15+ years of pharmaceutical/biotechnology industry experience with substantial progressive leadership responsibility within pharmacovigilance. - Demonstrated leadership of PV activities through late-stage development, regulatory approval, and commercial launch. - Experience establishing or significantly scaling a pharmacovigilance function, ideally within a small or mid-sized biotechnology company. - Experience interacting with senior executives, health authorities, strategic partners, and regulatory inspectors. Technical Expertise Strong working knowledge of: - Global pharmacovigilance regulations and regulatory reporting requirements - ICSR management and expedited reporting - Signal detection and signal management - Aggregate safety reporting - Benefit-risk assessment - Risk management planning and risk minimization - Safety governance - Safety database and PV technology environments - SDEAs and partner pharmacovigilance oversight - Vendor governance and outsourced PV models - PV quality systems, CAPAs, audits, and inspection readiness - Clinical-to-commercial PV transition Experience with commercial safety systems such as Oracle Argus Safety or equivalent validated safety database platforms is desirable. Leadership Competencies The successful candidate will demonstrate: - Builder mentality: Comfortable establishing infrastructure rather than inheriting a fully mature PV organization. - Strategic judgment: Ability to distinguish immediate launch-critical requirements from capabilities that can scale after commercialization. - Scientific rigor: Strong ability to interpret complex clinical and post-marketing safety information and translate it into actionable benefit-risk assessments. - Operational discipline: Ability to establish processes, governance, controls, metrics, and vendor accountability. - Cross-functional influence: Ability to work effectively with Clinical, Regulatory, Medical Affairs, Quality, Commercial, Legal, and executive leadership. - Risk-based decision making: Ability to identify material patient-safety and compliance risks and implement pragmatic solutions in a resource-conscious biotechnology environment. - Executive communication: Ability to communicate complex safety issues clearly and concisely to senior leadership and governance committees. - Hands-on leadership: Willingness to operate both strategically and tactically in a growing organization. ## Preferred Experience Particularly attractive candidates will have experience with several of the following: - First commercial product launch - Transition from clinical-stage to commercial-stage biotechnology - NDA or BLA submission and approval - U.S. and European product launches - Building or scaling an outsourced/hybrid PV operating model - Establishing post-marketing signal detection processes - Implementing or migrating a validated safety database - PSMF development and maintenance - FDA or European health authority PV inspections - Rare disease, oncology, specialty pharmaceutical, biologic, or other relevant therapeutic-area experience - Patient support programs and specialty pharmacy safety reporting - Commercial product complaint/adverse event reconciliation - Licensing, co-development, or co-commercialization partnerships Rezolute (RZLT) currently anticipates the base salary for the Director / Senior Director, PharmacovigilanceOperations role could range from $255,000 to $315,000 and will depend in part on the successful candidate’s geographical location and their qualifications for the role, including education and experience. This position will also be eligible for an annual performance bonus in accordance with the terms of the applicable plan (depending, in part, on company and individual performance and at the Company’s discretion on an individual basis). The compensation described above is subject to change and could be higher or lower than the range described based on current market survey data and the qualifications, education, experience, and geographical location of the selected candidate. Qualifying employees are eligible to participate in benefit programs such as: Health Insurance (Medical / Dental / Vision) Disability, Life & Long-Term Care Insurance Holiday Pay Tracking Free Vacation Program 401(k) Plan Match Educational Assistance Benefit Fitness Center Reimbursement We are an Equal Opportunity Employer and do not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class. ## About Rezolute ## Company Overview - **One-liner**: Rezolute is a late-stage rare disease biotechnology company developing ersodetug, a monoclonal antibody therapy for hypoglycemia caused by congenital and tumor hyperinsulinism. - **Entity Type**: Public (Nasdaq: RZLT) - **Headquarters**: Redwood City, California, United States (with an additional office in Louisville) - **Founded**: Not publicly available (IPO 2012) - **Founders**: Not publicly available ## Core Business - **Primary industry**: Biotechnology – rare disease therapeutics - **Target customers**: B2B – healthcare providers, patients, and payers; focuses on addressing severe unmet medical needs in hyperinsulinism - **Mission/purpose**: Significantly improve outcomes for individuals with hypoglycemia caused by hyperinsulinism ([rezolutebio.com – About](https://rezolutebio.com/job-openings/)) ## Products & Services - **Ersodetug (lead candidate)**: An intravenously administered human monoclonal antibody that allosterically binds to the insulin receptor, down‑modulating insulin action to restore normal glucose levels. Being developed for two indications: - **Congenital Hyperinsulinism (sunRIZE Phase 3 study)** – completed enrollment (May 2025) with 62 participants; topline results expected December 2025. - **Tumor Hyperinsulinism (upLIFT Phase 3 study)** – initiated mid‑2025; FDA agreed to a single‑arm open‑label design; topline results expected second half 2026. - Designations: Orphan Drug (US/EU), Rare Pediatric Disease, Breakthrough Therapy (US), PRIME (EU), ILAP (UK) ([ir.rezolutebio.com – 10-K](https://ir.rezolutebio.com/sec-filings/content/0001104659-25-090848/0001104659-25-090848.pdf)) ## Market Standing - **Valuation/Market Cap**: $317.7 million (as of recent data, per LinkedIn) ([linkedin.com](https://linkedin.com/company/rezolute)) - **Key Metric (Public)**: Annual revenue of $14.1 million (likely from grants or collaboration revenue; no product revenue yet) ([linkedin.com](https://linkedin.com/company/rezolute)) - **Notable Investors/Partners**: Not publicly available – company is publicly traded and does not disclose a lead investor list. Key partners include clinical trial sites and regulatory agencies (FDA, EMA). - **Growth Signals**: - Headcount: 50 employees (+2.9% YoY) ([linkedin.com](https://linkedin.com/company/rezolute)) - Phase 3 sunRIZE study fully enrolled; topline data pending December 2025. - Phase 3 upLIFT study enrolling with streamlined design; data expected second half 2026. - FDA granted Breakthrough Therapy Designation for tumor HI in May 2025. - Multiple regulatory designations accelerating development pathway. ## Competitive Advantages - **Unique mechanism**: Ersodetug acts downstream from beta cells at the insulin receptor, allowing it to potentially treat all forms of hyperinsulinism (genetic or acquired) regardless of underlying cause. - **Dosing convenience**: Half‑life >2 weeks enables monthly intravenous administration. - **Regulatory momentum**: Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy, PRIME, and ILAP designations provide expedited review, potential priority review voucher, and closer FDA/EMA collaboration. - **Pivotal data catalysts**: Two Phase 3 studies read out within ~12‑18 months, creating clear value inflection points. ## Strategic Focus - Execute the two ongoing Phase 3 trials (sunRIZE in congenital HI, upLIFT in tumor HI). - Assuming positive topline data from sunRIZE, submit a Biologics License Application (BLA) to the FDA for ersodetug in mid‑2026. - Continue to build commercial and medical affairs infrastructure (recent job postings indicate hires in Commercial Operations, Marketing, Payer Strategy, and Supply Chain) ([rezolutebio.com – Job Openings](https://rezolutebio.com/job-openings/)). ## Why Work Here - **Mission‑driven**: Employees work on therapies for ultra‑rare, life‑threatening conditions with high unmet medical need. - **Benefits**: Comprehensive health/dental/vision insurance, competitive salaries, annual bonus, 401(k) with company match, tuition assistance, on‑site meals, flexible spending accounts ([rezolutebio.com – Benefits](https://rezolutebio.com/job-openings/)). - **Work environment**: Hybrid/office policy not explicitly stated; roles are based in Redwood City (HQ) and Louisville. Recent openings include remote-friendly functions? Not confirmed. - **Growth opportunity**: Small company (~50 people) entering late‑stage development and pre‑commercial build‑out – employees can have broad impact and career advancement. - **Engineering culture**: For biotech, the focus is on clinical operations, regulatory, and commercial roles rather than traditional engineering. IT positions (Business System Engineer) exist. ## Sources 1. [linkedin.com – Rezolute company page](https://linkedin.com/company/rezolute) 2. [rezolutebio.com – Job Openings & Benefits](https://rezolutebio.com/job-openings/) 3. [ir.rezolutebio.com – SEC 10-K Filing (September 2025)](https://ir.rezolutebio.com/sec-filings/content/0001104659-25-090848/0001104659-25-090848.pdf) 4. [rezolutebio.com – Leadership page](https://rezolutebio.com/leadership/) ## Other roles at Rezolute - [Medical Writer II, Clinical/Regulatory](https://feeny.ai/job/medical-writer-ii-clinical-regulatory-rezolute-redwood-city-h43j74mshd1b) — Redwood City, CA - [Executive & Administrative Business Partner](https://feeny.ai/job/executive-administrative-business-partner-rezolute-redwood-city-c1620sbmm02k) — Redwood City, CA - [Manager, Statistical Programming](https://feeny.ai/job/manager-statistical-programming-rezolute-remote-g58ra51zr042) - [Manager, Quality Assurance](https://feeny.ai/job/manager-quality-assurance-rezolute-redwood-city-ea9hyav4h4dr) — Redwood City, CA - [Sr. Medical Science Liaison](https://feeny.ai/job/sr-medical-science-liaison-rezolute-remote-p0q0xz8s2neg) - [Senior Manager, External Supplier Operations](https://feeny.ai/job/senior-manager-external-supplier-operations-rezolute-redwood-city-pqxs0q5vsnyp) — Redwood City, CA - [Sr Director, Regulatory Affairs](https://feeny.ai/job/sr-director-regulatory-affairs-rezolute-redwood-city-wqvf8n5fvptf) — Redwood City, CA - [Head of Global Product Supply](https://feeny.ai/job/head-of-global-product-supply-rezolute-redwood-city-9yv4d2b9fg0s) — Redwood City, CA - [Director Program Manager, Product Launch (Rare Disease)](https://feeny.ai/job/director-program-manager-product-launch-rare-disease-rezolute-redwood-city-vn56yjrm5v16) — Redwood City, CA - [Sr. Director, Commercial Supply Chain](https://feeny.ai/job/sr-director-commercial-supply-chain-rezolute-redwood-city-e3ss6gz4cayw) — Redwood City, CA